Vivek Ramaswamy, founder of Axovant Sciences, acquired an experimental Alzheimer’s drug, intepirdine, from GlaxoSmithKline (GSK) in December 2014 for $5 million. 

GSK had previously discontinued the drug after it failed four clinical trials. https://t.co/yn3UzNI6fI